Anti-VEGF remains most expensive PBS drug
The Australian government spent $55 million more on anti-VEGF macular disease therapies in 2020-21 compared to the previous year, with ...
Tag: Eylea
New anti-VEGF therapies seeking Aussie approval
The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens ...
Novartis secures PBS recommendation for Beovu
An independent expert panel has recommended Novartis' treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related ...
Opthea treats first patient in Phase 3 nAMD trial
The first patient in the Phase 3 clinical trial of a Melbourne-based drug company’s novel therapy for neovascular age-related macular ...
Anti-VEGF becomes most expensive drug on PBS
The Australian government spent more than $610 million on anti-VEGF treatments during the past year, with aflibercept (Eylea) leapfrogging a ...
Roche’s faricimab meets primary endpoint in DME trial
Swiss drug giant Roche is poised to pursue regulatory clearance for its new faricimab antibody for diabetic macular edema (DME) ...
Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange
Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority ...
Opthea meets US and European regulators over Phase 3 trial
A Melbourne-based drug company is one step closer to starting Phase 3 clinical trials and pre-commercial development of its novel ...
Eylea biosimilar embarks on Phase 3 trial
A biopharmaceutical company that is developing cheaper anti-VEGF treatments for Australia and other markets has launched a global clinical trial ...
Drug developer hits major milestone with Lucentis biosimilar
A biopharmaceutical company that is developing cheaper anti-VEGF treatments for major global markets, including Australia, has reported positive results from ...